menu search

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose cohorts – – First VISTA-blocking antibody administered at a dose anticipated to be therapeutically relevant without eliciting dose-limiting toxicity – – Monotherapy data from Phase 1/2 study to be presented in […] The post Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC... Read More
Posted: Nov 3 2023, 20:05
Author Name: forextv
Views: 091631

Search within

Pages Search Results: